USA - NASDAQ:KALA - US4831192020 - Common Stock
ChartMill assigns a Buy % Consensus number of 82% to KALA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating | 
|---|---|---|---|
| 2025-09-29 | HC Wainwright & Co. | Downgrade | Buy -> Neutral | 
| 2025-09-17 | HC Wainwright & Co. | Maintains | Buy -> Buy | 
| 2025-09-11 | Oppenheimer | Maintains | Outperform -> Outperform | 
| 2025-09-08 | Mizuho | Initiate | Outperform | 
| 2025-05-23 | HC Wainwright & Co. | Maintains | Buy -> Buy | 
| 2025-04-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy | 
| 2025-02-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy | 
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy | 
| 2024-08-19 | Oppenheimer | Reiterate | Outperform -> Outperform | 
| 2024-05-17 | HC Wainwright & Co. | Maintains | Buy -> Buy | 
| 2024-04-02 | HC Wainwright & Co. | Maintains | Buy -> Buy | 
| 2024-04-01 | Oppenheimer | Reiterate | Outperform -> Outperform | 
| 2023-11-17 | HC Wainwright & Co. | Maintains | Buy -> Buy | 
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy | 
| 2023-05-10 | HC Wainwright & Co. | Reiterate | Buy | 
| 2023-05-01 | HC Wainwright & Co. | Reiterate | Buy | 
| 2023-04-12 | HC Wainwright & Co. | Maintains | Buy | 
| 2023-03-27 | HC Wainwright & Co. | Reiterate | Buy | 
| 2023-03-06 | HC Wainwright & Co. | Maintains | Buy | 
| 2022-08-15 | HC Wainwright & Co. | Maintains | Buy | 
| 2022-05-24 | HC Wainwright & Co. | Maintains | Buy | 
| 2022-05-17 | HC Wainwright & Co. | Maintains | Buy | 
| 2021-08-06 | JP Morgan | Downgrade | Overweight -> Neutral | 
| 2021-08-06 | HC Wainwright & Co. | Maintains | Buy | 
| 2021-05-06 | HC Wainwright & Co. | Maintains | Buy | 
10 analysts have analysed KALA and the average price target is 31.37 USD. This implies a price increase of 3973.38% is expected in the next year compared to the current price of 0.77.
The consensus rating for KALA BIO INC (KALA) is 82 / 100 . This indicates that analysts generally have a positive outlook on the stock.